Can Molbio Diagnostics IPO deliver long-term growth for high risk investors?
Molbio Diagnostics plans to raise ₹200 crore through a fresh issue and ₹740 crore via an offer for sale in its upcoming IPO, reducing the promoter group's stake to 43%. The company, which serves over 90 countries and generates more than 80% of its revenue from government and international aid agencies, has shown significant financial growth, with a 31.5% increase in revenue and a 40.2% rise in net profit between FY24 and FY26. Investors with a high-risk appetite may find potential in this IPO, despite customer concentration risks and a high price-earnings multiple of 57.